Covid19 vax jab linked to blood clots warning to public Part 1, Dr. Hooman Noorchashm warning to FDA and public Jan. 26, 2021, Injecting those with natural immunity
Covid19 vax jab linked to blood clots warning to public Part 1, Dr. Hooman Noorchashm warning to FDA and public Jan. 26, 2021, Injecting those with natural immunity
Dr. Hooman Noorchashm letter as email to FDA Jan. 26, 2021.
“Date: Tue, Jan 26, 2021 at 10:02 AM
Subject: COVID-19 VACCINE WARNING — Vaccine Directed Immune Response In Asymptomatic Carriers And The Convalescent
To: Woodcock, Janet <Janet.woodcock@fda.hhs.gov>, Marks, Peter <Peter.Marks@fda.hhs.gov>
Cc: June MD, Carl H <XXXXX>, Michael Paasche-Orlow <XXXXX>, Gruber, William C <Bill.Gruber@pfizer.com>, <albert.bourla@pfizer.com>, Constant, Gerri S <gsconstant@cbs.com>, hornblowers <hornblowers@cbsnews.com>, Stark, Karl <kstark@inquirer.com>, Sutton, Charlotte <CSutton@inquirer.com>, Kamp, Jon <jon.kamp@wsj.com>, mark.maremont <mark.maremont@wsj.com>, Loftus, Peter <peter.loftus@wsj.com>, <jared.hopkins@wsj.com>, <betsy.mckay@wsj.com>, Peter Lurie <plurie@cspinet.org>, Kris Mamula <kmamula@post-gazette.com>, Karen Weintraub <weintraubkaren@gmail.com>, Caplan, Arthur <arthur.caplan@nyulangone.org>,
Dear Drs. Woodcock and Marks,
I write here to present a warning and a, nearly certain, prognostication to you as our lead FDA regulators and public health experts.
As you know, the SARS-CoV-2 virus has tropism for the vascular endothelium, among other tissues and organs. This fact was captured in a Lancet paper published in April 2020:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30937-5/fulltext
As you also know it appears that the ACE-2 receptor on endothelium is the portal for viral entry into endothelial cells — and it seems that endothelial injury from the virus or from the inflammatory reaction it incites, is the reason why many COVID-19 patients experience thromboembolic complications.
Image for postImage for post
Dr. Willaim Gruber, Pfizer’s SVP of Vaccine Clinical Research and Development, received this email of warning.
So it is a matter of certainty that viral antigens are present in the endothelial lining of blood vessels in all persons with active or recent SARS-CoV-2 infection — irrespective of whether they are symptomatic or convalescent.
I am writing to warn that it is an almost certain immunological prognotication that if viral antigens are present in the tissues of subjects who undergo vaccination, the antigen specific immune response triggered by the vaccine will target those tissues and cause tissue inflammation and damage.
Image for postImage for post
Dr. Janet Woodcock, acting FDA commissioner, received this email warning of the potential immunological danger of vaccinating recently convalescent or asymptomatic carriers of SARS-CoV-2.
Most pertinently, when viral antigens are present in the vascular endothelium, and especially in elderly and frail with cardiovascular disease, the antigen specific immune response incited by the vaccine is almost certain to do damage to the vascular endothelium. Such vaccine directed endothelial inflammation is certain to cause blood clot formation with the potential for major thromboembolic complications, at least in a subset of such patients. If a majority of younger more robust patients might tolerate such vascular injury from a vaccine immune response, many elderly and frail patients with cardiovascular disease will not.
Therefore, it is my respectful request that FDA, in collaboration with Pfizer and Moderna, immediately and at the very minimum, institute clear recommendations to clinicians that they delay immunization in any recently convalescent patients, as well as, any known symptomatic or asymptomatic carriers — and to actively screen as many patients with high cardiovascular risk as is reasonably possible, in order to detect the presence of SARS-CoV-2, prior to vaccinating them.
Image for postImage for post
Dr. Peter Marks, Chief of FDA’s Center for Biological Evaluation and Research, is the lead regulator responsible for ensuring proper evaluation of efficacy and safety for all vaccine products.
A potential reasonable solution, especially in the nursing home setting, would be to use antibody screening as a surrogate means of excluding/delaying vaccination in persons who might have been exposed to the virus and have viral antigens lingering in their tissues.
The goal of maximally and quickly vaccinating the population is the correct public health goal. It will save many lives and likely our nation — certainly population level vaccination will save far more lives than any given vaccine related complication might compromise. But, in the present national emergency, simply because we know that the majority of citizens in our society will benefit from vaccination cannot justify a regulatory and corporate failure to mitigate against known and rationally prognosticated dangers to the minority subset or persons at risk of harm.
As an immunologist with a good understanding of how antigen specific immune responses could cause organ and tissue specific damage, I am recommending to you, as our lead FDA regulators, not to gloss over the real possibility that vaccinating persons with pre-existing SARS-CoV-2 viral antigens in their tissues could cause that subset of people grave harm — and especially the frail with cardiovascular disease.
Additionally, if the immunological risk I am prognosticating herein is in reality material, over the next months as millions more Americans are immunized, it will become quite visible to the public.
Can you imagine if the public, without having received any real warning from FDA, becomes aware of an increasing number of such vascular/thromboembolic complications? What do you suppose will happen to the level of “vaccine hesitancy” then? And, what kind of accountability do you think the public will demand from our experts and federal regulators — especially if they knew, or should have known, that this immunological danger might exist?
The aim of benefiting the majority of our public and saving the nation from this pandemic by quick and aggressive vaccination is an ethically sound one — but where we know of real or likely risks of harm and mortality, we ought to mitigate the risks to those in potential harms way. So doing is the only reasonable, ethical, and likely legal option you can pursue as public health regulators — for in America, we no longer sacrifice the lives of minority subsets of people for the benefit of the majority.
Drs. Woodcock and Marks, a professor of mine in medical school used to tell his students “the eyes do not see what the mind does not know”….Thromboembolic complications, 10–20 days following activation of a vaccine induced antigen specific immune response, in elderly frail vasculopaths, will not register as classical “vaccine related complications”….But SARS-CoV-2 is a virus with tropism for the vascular endothelium….So, our Pfizer and Moderna vaccines could easily direct an antigen specific immune attack to that very target organ.
I ask that you carefully and wisely consider my immunological prognostication and warning here — FDA, Pfizer and Moderna ought not miss this risk of harm to what is a daily increasing proportion of the population during this ongoing pandemic. Vaccinating patients with occult SARS-CoV-2 infections or lingering viral antigens, is a clear and present potential danger to the health of these patients.
With respect and in friendship,
Hooman Noorchashm MD, PhD.”
From above:
“Such vaccine directed endothelial inflammation is certain to cause blood clot formation with the potential for major thromboembolic complications, at least in a subset of such patients. If a majority of younger more robust patients might tolerate such vascular injury from a vaccine immune response, many elderly and frail patients with cardiovascular disease will not.”
This could account for some patients having adverse reactions or dying suddenly.
Dr. Hooman Noorchashm Bio.
“Dr. Hooman Noorchashm is a thoracic surgeon in Yardley, Pennsylvania. He received his medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice for more than 20 years.
Thoracic Surgery
Cardiac and thoracic surgeons specialize in the surgical treatment of diseases of the chest and heart. Thoracic surgeons and cardiac surgeons have the same general training and certified by the same board. Cardiac surgery deals with the heart, and thoracic surgery focuses on the lungs. Cardiac surgeons deal with heart transplant, heart disease, coronary artery disease, heart valve blockages, heart failure. Thoracic surgeons focus on the lungs, esophagus, and other chest organs and they treat lung cancer and emphysema.”
